NCT02704858: Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 49 planned
- Started
- 1 Aug 2017
- Primary completion
- 30 Nov 2026
- Arms
- NEO100 Phase 1, NEO100 Phase 2A
- Results
- None posted
- 10 Mar 2016: Trial registered
- 1 Aug 2017: Trial started